A 2012 clinical update for internists in adult nonalcoholic fatty liver disease

Panminerva Medica

Volumn 54, Issue 1, 2012, Pages 29-37

  Younossi, Z M ^a,b   Venkatesan, C ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Disease progression; Fatty liver; Therapeutics

Indexed keywords

ADULT; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; HUMAN; MALE; PREDICTIVE VALUE; PROGNOSIS;

ADULT; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84858830168     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231-7.
2. Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do Diabetes Metab Res Rev 2011;27:419-24.
3. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011;35:23-8.
4. Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: A narrative review. Gastroenterol Hepatol 2011 [Epub ahead of print].
5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113-21. (Pubitemid 41002048)
6. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73. (Pubitemid 46489550)
7. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-8.
8. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12.
9. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-49.
10. Arslan U, Türkoǧlu S, Balcioǧlu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007;18:433-6. (Pubitemid 47262963)
11. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-9.
12. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891
13. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
14. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16.
15. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2011 [Epub ahead of print]
16. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;361349-54.
17. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
18. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006;101:2247-53. (Pubitemid 44477551)
19. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005;28:1222-4. (Pubitemid 40616643)
20. Marchesini G, Bugianesi E, Forlani G, Cenelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. Enatum in: Hepatology 2003;38:536.
21. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265-9.
22. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2011;33:525-40.
23. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54. (Pubitemid 46631552)
24. Nafldscore. Homepage. [Internet]. Available from nafldscore.com [cited 2011, Nov 21].
25. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-8.
26. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008;18:1430-7.
27. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-60. (Pubitemid 351280713)
28. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-51.
29. Wong VW, Chan HL. Transient elastography. J Gastroenterol Hepatol 2010;25:1726-31.
30. American Gastroenterological Association. American Gastroenterological Association Medical Position Statement: Nonalcoholic Fatty Liver Disease. Gastroenterology 2002;123:1702-4.
31. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017-44.
32. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410-5.
33. Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-7):1-23.
34. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33
35. Younossi ZM, Stepanova M. Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. Hepatology 2011;54:1167-78.
36. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
37. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
38. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
39. Wang RT, Koretz RL, Yee HF Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115:554-9. (Pubitemid 37352802)
40. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
41. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81. (Pubitemid 40769044)
42. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
43. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL et al. Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010;33:2156-63.
44. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011;17:3377-89.
45. Centers for Disease Control and Prevention. Homepage [Internet]. Available from www.cdc.gov [cited 2011, Nov 21].
46. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independem effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76.
47. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-12.
48. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106:460-8.
49. Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H et al. Alcohol consumption appears to protect against nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:378-88.
50. Cotrim HP, Freitas LA, Alves E, Almeida A, May DS, Caldwell S. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009;21:969-72.
51. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947-54. (Pubitemid 351945562)
52. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010;32:1211 -21.
53. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
54. Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011; 15:1 -116.
55. Chalasani N, Aljadhey H, Kesterson J, Munay MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92. (Pubitemid 38552793)
56. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Beider R; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63. (Pubitemid 350155527)
57. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106:71-7.
58. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronicaliy elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007;47:135-41.
59. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22.
60. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-6.
61. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
62. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300:2123-33.
63. Adinolfi LE, Restivo L. Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol 2011;5:147-50.
64. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011-9.
65. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 Supplementation and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. J Hepatol 2011 Oct 21 [Epub ahead of print].
66. Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011;3:265-7.
67. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10:49.
68. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S et al. Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus. Hepatogastroenterology 2011;58.
69. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
70. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev2010;CD007340.
71. Dixon JB. Surgical treatment for obesity and its impact on nonalcoholic steatohepatitis. Clin Liver Dis 2007;11:141-54, ix-x. (Pubitemid 46829970)